Manuscript Writing Service
International Journal of Orthopaedics Sciences
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal

International Journal of Orthopaedics Sciences

2020, Volume 6 Issue 3

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

Author(s): Dr. Lenin Ligu and Dr. Moji Jini
Abstract: Background: Introduction: Total hip arthroplasty (THA) is a successful surgical procedure for reducing pain and improving physical function in osteoarthritis. It is one of the most effective orthopaedic procedures.
Material and methods: Patients were eligible for the study if they were aged 18 years or older and were scheduled for total hip arthroplasty. Patients were ineligible if they were scheduled to undergo staged, bilateral hip arthroplasty were pregnant or breastfeeding, had active bleeding or a high risk of bleeding, or any disorder contraindicating the use of Rivaroxaban/enoxaparin that might necessitate enoxaparin dose adjustment.
Results: Of the 52 patients enrolled in study, 52 patients were randomized to receive either Rivaroxaban (n=26) or enoxaparin (n=26). The baseline demographic characteristics of the two randomized treatment groups are well balanced as described in Table 1. The surgical characteristics are described in Table 2.
Conclusion: Rivaroxaban, given as a once-daily 10 mg fixed dose 6–8 h postoperatively, is the first new oral anticoagulant to significantly reduce the incidence of venous thromboembolism after total knee arthroplasty, compared with enoxaparin 30 mg twice daily, starting 12–24 h postoperatively, without a significant difference in the risk of major or clinically relevant bleeding.
Pages: 90-95  |  115 Views  3 Downloads
How to cite this article:
Dr. Lenin Ligu and Dr. Moji Jini. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. International Journal of Orthopaedics Sciences. 2020; 6(3): 90-95. DOI: 10.22271/ortho.2020.v6.i3b.2183
International Journal of Orthopaedics Sciences